Tenax Therapeutics is trading 6.69% up now at $1.83, extending its rebound after the August 10, 2026 collapse caused by disappointing Phase 3 LEVEL trial results.
- The study missed its primary and key secondary endpoints, pressuring the company’s regulatory outlook.
- Broader risk appetite is also supporting the move as major U.S. indexes rise following cooler inflation data.